Molecular Stress-inducing Compounds Increase Osteoclast Formation in a Heat Shock Factor 1 Protein-dependent Manner by Chai, RC et al.
Molecular Stress-inducing Compounds Increase Osteoclast
Formation in a Heat Shock Factor 1 Protein-dependent
Manner*
Received for publication,October 27, 2013, and in revised form, March 10, 2014 Published, JBC Papers in Press, April 1, 2014, DOI 10.1074/jbc.M113.530626
Ryan C. Chai‡, Michelle M. Kouspou‡, Benjamin J. Lang‡, Chau H. Nguyen‡, A. Gabrielle J. van der Kraan‡§,
Jessica L. Vieusseux‡, Reece C. Lim‡, Matthew T. Gillespie‡§, Ivor J. Benjamin¶, Julian M. W. Quinn‡§1,
and John T. Price‡1,2
From the ‡Department of Biochemistry andMolecular Biology, Monash University, Clayton, Victoria 3800, Australia, §Prince
Henry’s Institute, Clayton, Victoria 3168, Australia, the ¶Division of Cardiovascular Medicine, Medical College ofWisconsin,
Milwaukee, Wisconsin 53226, and the College of Health and Biomedicine, Victoria University, St. Albans, Melbourne,
Victoria 8001, Australia
Background: HSP90 inhibitors increase osteoclast formation and bone loss.
Results: Altered Hsf1 activity impacts the ability of stress-inducing compounds to modulate osteoclast formation.
Conclusion: Hsf1 plays an important role in stress-associated osteoclast formation, potentially via MITF.
Significance:We identified a novel pathway whereby agents inducing stress can enhance osteoclast formation.
Many anticancer therapeutic agents cause bone loss, which
increases the risk of fractures that severely reduce quality of life.
Thus, in drug development, it is critical to identify and under-
stand such effects. Anticancer therapeutic and HSP90 inhibitor
17-(allylamino)-17-demethoxygeldanamycin (17-AAG) causes
bone loss by increasing osteoclast formation, but the mecha-
nism underlying this is not understood. 17-AAG activates heat
shock factor 1 (Hsf1), the master transcriptional regulator of
heat shock/cell stress responses, which may be involved in this
negative action of 17-AAG upon bone. Using mouse bone mar-
row and RAW264.7 osteoclast differentiation models we found
that HSP90 inhibitors that induced a heat shock response also
enhanced osteoclast formation, whereas HSP90 inhibitors that
did not (including coumermycin A1 and novobiocin) did not
affect osteoclast formation. Pharmacological inhibition or
shRNAmir knockdown of Hsf1 in RAW264.7 cells as well as the
use of Hsf1 null mouse bone marrow cells demonstrated that
17-AAG-enhanced osteoclast formation was Hsf1-dependent.
Moreover, ectopic overexpression of Hsf1 enhanced 17-AAG
effects upon osteoclast formation. Consistent with these
findings, protein levels of the essential osteoclast transcrip-
tion factor microphthalmia-associated transcription factor
were increased by 17-AAG in an Hsf1-dependent manner. In
addition to HSP90 inhibitors, we also identified that other
agents that induced cellular stress, such as ethanol, doxoru-
bicin, and methotrexate, also directly increased osteoclast
formation, potentially in an Hsf1-dependent manner. These
results, therefore, indicate that cellular stress can enhance
osteoclast differentiation via Hsf1-dependent mechanisms
and may significantly contribute to pathological and thera-
peutic related bone loss.
Maintaining bone mass and quality is critical for sustained
health and quality of life by preventing fracture (1). For this
reason, bone undergoes continual remodeling throughout
adult life to optimize bone quality and structural integrity. This
remodeling process involves cycles of bone resorption and for-
mation, mediated by osteoclasts and osteoblasts, respectively
(2, 3). Many factors can negatively impact bone health, includ-
ing a poor diet, gonadal hormonal insufficiency, pathological
insult, as well as a range of therapeutic agents (4–7) that often
compound the loss of bone mass seen with aging. Factors that
are deleterious to bone generally cause a net increase in the
formation of the specialized bone-resorbing cell, the osteoclast,
causing sustained bone loss that can result in low bonemass, i.e.
osteopenia or osteoporosis (8, 9), that is not compensated for by
increased bone formation. Such bone loss is associated with
decreased bone strength and, thus, an increased fracture risk,
particularly in the spine, hip, and wrist, with any resulting frac-
tures ultimately leading to a severely diminished quality of life
and increased rate of mortality, particularly in elderly patients
(10). Localized rapid bone loss may also cause pain and hyper-
calcemia (4).
It is increasingly recognized that chemotherapeutic agents
have amajor negative impact uponbone by increasing bone loss
and fracture riskmore rapidly and severely than seen in normal
age-related bone loss (4, 6). Although both hormonal and non-
hormonal cancer therapies promote bone loss by inducing
hypogonadism, chemotherapeutics can also directly impact
osteoclasts (as well as the bone-forming osteoblasts) to cause
loss of bone mass and structural integrity, although the mech-
anisms that underlie this have still to be fully elucidated (4,
11–13). Because of the effectiveness of a number of cancer
treatments providing improved survival rates, especially in
older patients who may already have low bone mass, it is of
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increasing importance to determine the effect of therapeutics
on bone turnover and bone loss. Moreover, it is important to
identify themechanisms by which anticancer agentsmay result
in bone loss so that preventative measures, such as administra-
tion of antiosteolytic treatments, may be designed effectively.
The process of osteoclast formation is fundamental to the
resorption of bone during both physiological and pathophysio-
logical bone resorption. Osteoclasts are multinucleated, hema-
topoietically derived cells (3) that are highly active and rela-
tively short-lived. Thus, their formation is a highly regulated
point of control for bone resorption and is dependent upon the
action of RANKL,3 a TNF-related molecule whose production
is locally regulated by many osteotropic hormones. RANKL
typically acts in concert with M-CSF, a survival and prolifera-
tion factor for osteoclast progenitors and macrophages.
RANKL, through interaction with its cognate receptor RANK,
activates a cascade of critical transcription factors in osteoclast
progenitors, notably involving NFB, AP-1 (cFos/cJun dimer),
NFATc1, andMITF.These factors, in turn, activate osteoclastic
gene expression and induce cell fusion, resulting in mature,
functional, multinucleated osteoclasts (14, 15).
Heat shock protein 90 (HSP90) is amolecular chaperone that
is required for the stability and functionality of a diverse range
of proteins (16). In particular, its action is critical for the stabil-
ity and activity of mutated and overexpressed oncogenic pro-
teins that enhance the survival, growth, and invasive potential
of cancer cells (16, 17). Consistent with this, HSP90 is highly
expressed in many tumor types and has been associated with
poor patient outcomes (16–18). Thus, HSP90 has emerged as a
major cancer therapeutic target and, as such, a number of
HSP90 inhibitors have been developed, many of which have
undergone or are currently in clinical trials (19).
We have found previously that the geldanamycin-derived
HSP90 inhibitor and anticancer agent 17-AAG increases bone
loss in mouse models through the direct stimulation of oste-
oclast formation (20). Furthermore, although 17-AAG proved
to be effective in reducing the tumor burden at extraosseous
sites, it actually increased the tumor burden within the bone
and caused elevated bone loss even in the absence of tumor cells
(20). Increased tumor growth in bone probably reflects the well
characterized effects of the release of tumor growth factors
from the bone matrix and is, therefore, secondary to the bone
destruction caused by the pro-osteoclastic effects of 17-AAG.
Consistentwith our findings, Yano et al. (21) demonstrated that
17-AAG treatment enhanced prostate tumor growth in the
bones of mice, which could be abrogated by the administration
of inhibitors of osteoclast formation and function. In addition
to 17-AAG,we have demonstrated that other structurally unre-
lated HSP90 inhibitors also enhance osteoclast formation (20,
22). To date, the mechanism by which HSP90 inhibitors stim-
ulate osteoclast formation has not been clearly defined,
although Src kinase and the elevated expression of the essential
osteoclast transcription factor microphthalmia-associated
transcription factor (MITF) may play roles (21, 22). However,
HSP90 inhibition itself seems unlikely to be directly critical in
17-AAG actions on osteoclasts because many of the RANKL
signaling pathways required for osteoclast formation (e.g.NFB
activation) are at least partly HSP90-dependent.
An alternative possibility is that the ability of 17-AAG to
activate the transcription factor heat shock factor 1 (Hsf1) may
play a central role in its effects on osteoclasts. Hsf1 is a critical
regulator of stress responses inmammalian cells and is essential
for the response to a broad range of stress stimuli, including the
regulation of heat shock proteins (HSPs) (23–25). Fundamental
to this response is the fact that Hsf1 associates with HSP90
under normal conditions, maintaining Hsf1 in an inactive
monomeric state (26, 27). However, upon 17-AAG binding to
the N-terminal ATPase domain of HSP90 or upon cellular stress,
Hsf1 dissociates from theHSP90 complex, forming homotrimeric
complexes, undergoes phosphorylation and SUMOylation (28),
and binds to heat shock element sites within the promoters of
target genes (28, 29).This results in a characteristic patternof gene
expression that is observed during stress (e.g. elevated levels of
HSP70 and other HSPs), aiding cell survival. Thus, we examined
whether the Hsf1-mediated stress response induced by HSP90
inhibition is responsible for enhancing osteoclast formation.
In this study, we report that the effects of 17-AAG upon
osteoclast formation are indeed Hsf1-dependent and that, con-
sistent with this, other Hsf1-inducing stressors have similar
effects. Moreover, within the context of the stress response, we
found that Hsf1 plays amajor role in enhancing the levels of the
critical osteoclast formation factor MITF. Our results impli-
cate, for the first time, the role of Hsf1 in osteoclast formation
and the influence of stress-induced MITF expression, which
points to a direct effect of cell stress andMITF in inducing bone
loss that may be important in many diseases that affect bone.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies—The HSP90 inhibitors 17-AAG,
17-DMAG, and radicicol were obtained from LC Labs
(Woburn, MA), and coumermycin A1 and novobiocin were
obtained from Sigma-Aldrich (Castle Hill, NSW, Australia).
KNK437 was a gift from Kaneka Corp. (Takasago, Japan), and
quercetin, methotrexate, and doxorubicin were purchased
from Merck Millipore (Kilsyth, VIC, Australia). Anti-HSP70
(HSPA1A) antibody (catalog no. ADI-SPA-812) was purchased
from Enzo Life Sciences (San Diego, CA). Anti-HSP105/110
(HSPH1) antibody (catalog no. SC-6241) was purchased from
Santa Cruz Biotechnology (Dallas, TX). The pan anti-actin
antibody (catalog no.MS-1295-P) was purchased fromThermo
Fisher Scientific (Scoresby, VIC, Australia), and the anti-Hsf1
antibody (catalog no. 4356) was obtained from Cell Signaling
Technology (Danvers, MA). IgG HRP-conjugated secondary
antibodies for immunoblotting were purchased from Thermo
Fisher Scientific. Recombinant murine soluble RANKL
(RANKL158–316-GST fusion protein) was obtained fromOrien-
tal Yeast Co. (Tokyo, Japan), and human M-CSF and TGF
(TGF1 isoform) were from R&D Systems (Minneapolis, MN).
L-cell conditioned medium (a source of secreted murine
3 The abbreviations used are: RANKL, receptor activator of nuclear factor B
ligand; MITF, microphthalmia-associated transcription factor; 17-AAG,
17-(allylamino)-17-demethoxygeldanamycin; 17-DMAG, 17-dimethylami-
noethylamino-17-demethoxygeldanamycin; HSP, heat shock protein;
TRAP, tartrate-resistant acid phosphatase; MEM, minimal essential medi-
um; BMM, bone marrow macrophage(s); MNC, mononuclear cell; ANOVA,
analysis of variance.
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M-CSF) was prepared as described by Yeung et al. (30). For tar-
trate resistant acid phosphatase (TRAP) histochemical staining,
fast red violet LB salt (F-1625), naphthol AS-MX phosphate, and
dimethylformamide were purchased from Sigma-Aldrich.
Animals—C57Black/6 mice were obtained from Monash
Animal Services (Monash University, Clayton, VIC, Australia).
Themice were maintained at theMonashMedical Centre Ani-
mal Facility (Clayton, VIC, Australia) according to procedures
approved by the Monash Medical Centre Animal Ethics Com-
mittee B (Clayton, VIC, Australia), authorization no. MMCB-
2011/19. The C;129-Hsf1tm1Ijb/J (stock no. 010543) (31) were
purchased from The Jackson Laboratories (Bar Harbor, ME)
and maintained in the Animal Resource Laboratories of
Monash University (Clayton, VIC, Australia) according to
standard husbandry and breeding procedures approved by
the Monash Animal Research Platform (MARP) 2 Animal
Ethics Committee (Clayton, VIC Australia), authorization
no. SOBSB/B/2010/28BC. Mice were maintained on a
BALB/cx 129SvEV background, and intercrossed Hsf1/
mice were used to generateHsf1/,Hsf1/, andHsf1/mice.
Mouse genotypes were determined by PCR according to the
standard protocol for the C;129-Hsf1tm1Ijb/J strain provided
by The Jackson Laboratory. All mice used in the experiments
were age-matched females.
Cell Lines and Culture—RAW264.7 cells were purchased
from the ATCC and were maintained in minimal essential
medium- (MEM) (Invitrogen) containing 10% FBS (Thermo
Fisher Scientific), penicillin (10000 units/ml), and streptomycin
(10000 units/ml) (Invitrogen), and HEPES (Invitrogen). All
osteoclast formation assays utilized this medium (MEM/FBS).
Primary bone marrow cells for culture were immediately iso-
lated from humanely killed, 6- to 12-week-old mice by flushing
the bone marrow cavity of the long bones with PBS in accor-
dance with theMARPAnimal Ethics Committee (Monash Uni-
versity, Clayton, VIC, Australia) authorization MARP/2011/
048. Primary bone marrow macrophage (BMM) cultures were
maintained in L-cell conditionedmedium to induce BMMpro-
liferation, as described previously (32) in RPMI 1640 medium
(Invitrogen) supplemented with penicillin and streptomycin
and 10% heat-inactivated FBS (MEM/HIFBS). All cells were
maintained in a 37 °C incubator in a humidified atmosphere
containing 5% CO2.
Hsf1 shRNAmir Knockdown and Hsf1 Ectopic Overexpression—
For Hsf1 knockdown, GIPZ lentiviral shRNAmir constructs
(V2LMM_226824, V2LMM_82329, V2LMM_82328, V3LMM_
415511, andV3LMM_415512) targeted towardmouseHsf1 and a
GIPZ non-silencing control lentiviral shRNAmir construct
(RHS4346) were purchased from Thermo Scientific. The non-si-
lencing control and the targeted mouse GIPZ shRNA constructs
were transiently cotransfectedwithpsPAX2andpMD2.Gpackag-
ing constructs into HEK293T cells using Lipofectamine LTX
according to the instructions of the manufacturer (Invitrogen).
The medium was replaced 16 h later, and, after a further 24 h,
the lentiviral-conditioned medium was collected and filtered
using a 0.45-m filter. RAW264.7 cells were transduced by the
addition of the lentiviral-conditioned medium for a period of
24 h with the addition of 10 mg/ml of Polybrene. Cells were
then grown in standard medium, and transduced cells were
selected on the basis of GFP expression using FACS (Flowcore
Platform,MonashUniversity) with the selection gates being set
to normalize GFP fluorescence intensity between the non-si-
lencing and Hsf1-silencing shRNAmir-expressing cells. The
most efficient knockdowns were achieved by using the
V3LMM_415512 andV2LMM_82329 shRNAmirs, whichwere
used for subsequent experiments and are referred to as mir4
and mir5, respectively.
To ectopically overexpress mouse Hsf1 in RAW264.7 cells, a
retroviral expression system was employed. The pBABE-Hsf1-
IRES-mCherry retroviral construct was generated by excision
of mouse Hsf1 from the Hsf1 construct pcDNA3.1() mHsf1
(provided by Richard Voellmy, University of Miami, FL) using
HindIII endonuclease refilled by T4DNApolymerase to gener-
ate blunt ends, and this was further digested with EcoRI endo-
nuclease. The resulting product was then ligated with pBABE-
puro-IRES-mCherry (33) that had been linearized by BamHI
digestion, end-filled with T4 DNA polymerase, and then
digested with EcoRI endonuclease. The correct orientation of
the mHSF1 insert was confirmed by diagnostic endonuclease
digestion.HEK293T cells were cotransfectedwith pCL-Ampho
packaging vector (Imgenex, San Diego, CA) and pBABE-Hsf1-
IRES-mCherry using Lipofectamine LTX (Invitrogen). Retrovi-
ral-conditioned medium generation, RAW264.7 transduction,
and selection of mCherry-expressing transduced cells by FACS
were performed according to the lentiviral approaches stated
previously.
Osteoclast Progenitor Differentiation and Survival Assays—
Osteoclasts were generated by culturing RAW264.7 cells for a
6-day period in 96-well plates at a density of 5 103 cells/well in
MEM/FBS, 20 ng/ml RANKL and in the presence or absence
(vehicle control) of HSP90 inhibitors and other stress-inducing
agents, as indicated under “Results.” The medium and the
agentswere replaced at day 3, and on day 6, cells were fixedwith
4% formaldehyde and histochemically stained for TRAP as
described previously (34). TRAP-positive multinucleated cells
(MNCs) containing three or more nuclei per cell, quantified
using an inverted light microscope, were counted as oste-
oclasts. To generate osteoclasts from primary murine cells,
bone marrow cells were flushed from bisected long bones of
C57black6/J, wild-type (Hsf1/), heterozygous (Hsf1/), or
knockout (Hsf1/) C;129-Hsf1tm1Ijb/J mice with PBS. Cells
were centrifuged and then resuspended in MEM/FBS. Bone
marrow cells (105 cells/well) were stimulated by 20 ng/ml
RANKL and 25 ng/mlM-CSF in the presence or absence of the
HSP90 inhibitor 17-AAG for 6 days. Cells were then fixed and
stained histochemically for TRAP and osteoclast numbers
counted. For BMM preparation for Western blotting, bone
marrow cells (106 cells/ml) were suspended in RPMI/HIFBS
supplemented with 30% L-cell-conditioned medium (30, 32),
incubated at 37 °C in a humidified atmosphere containing 5%
CO2 for 3 days, and then, the non-adherent cell fraction was
removed. The resulting adherent proliferating cells were then
prepared for analysis. These cells were able to form numerous
osteoclasts with RANKL/M-CSF treatment, as described previ-
ously (32). For cell survival assays RAW264.7 cells were seeded
at 5 103 cells/well and treatedwith a range ofHSP90 inhibitor
concentrations. After a period of 96 h, cells were fixed in 50%
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TCA at 4 °C for 1 h, followed by five washes in distilled water.
Cells were stained with sulforhodamine B (Sigma-Aldrich),
rinsed, and then cell-bound sulforhodamine B was solubilized
in 150 l of 10 mM Tris-HCl (pH 10.5). The absorbance at 550
nm was measured by spectrophotometry using a Multiskan FC
absorbance plate reader (Thermo-Lab Systems, MA).
Immunoblot Analysis—Immunoblot analysis was performed
as described previously (20, 22, 35). Briefly, cell lysates were
generated using modified radioimmune precipitation assay
buffer (50 mmol/liter Tris-HCl (pH 7.4), 1% Nonidet P-40,
0.25% sodium deoxycholate, 150 mmol/liter NaCl) containing
phosphatase and protease inhibitor mixture (Sigma-Aldrich),
sonicated, and then clarified by centrifugation. Protein concen-
trations were determined using the BCA protein assay accord-
ing to the instructions of the manufacturer (Thermo Fisher
Scientific). Cell lysates were run on 4–12% BisTris gradient
SDS-PAGE electrophoresis gels with MES SDS running buffer
(Invitrogen) under reducing conditions and transferred to
Immobilon-P PVDF membranes (Merck Millipore). Mem-
branes were blocked for 1 h with 3% milk powder (Diploma,
Fonterra Food Services, Mount Waverley, Australia) dissolved
in PBST (PBS 0.1% Tween 20). Membranes were then incu-
bated overnight at 4 °C with appropriate primary antibodies.
Immunoblot visualization was achieved by incubation with
appropriate IgG HRP-conjugated secondary antibodies and an
ECL detection system (Supersignal West Pico, Thermo Fisher
Scientific) according to the instructions of the manufacturer.
Statistical Analysis—Data were analyzed using Prism 5 soft-
ware (GraphPad, San Diego, CA), and statistical significance
was determined using ANOVA/Dunnett’s post hoc test. Quan-
titative data are presented as mean  S.E. of three or more
pooled experiments, and significance is represented graphically
by *, p 0.05; **, p 0.01; or ***, p 0.001.
RESULTS
HSP90 Inhibitors Enhance Osteoclast Formation in Associa-
tion with Induction of the Heat Shock Response—To investigate
the role of the HSR and, more specifically, Hsf1, in 17-AAG
actions on osteoclastogenesis, we first examined the effects of
different HSP90 inhibitors on the maturation of murine
RAW264.7 cells, a bipotential osteoclast/macrophage progeni-
tor cell line that responds strongly to RANKL treatment by
forming osteoclasts. RAW264.7 cells were treated with a sub-
maximal concentration of RANKL (20 ng/ml) that is sufficient
to cause low levels of osteoclast formation over 6 days of incu-
bation. Osteoclast formation was completely dependent on
RANKL treatment; i.e. in cultures where RANKL was omitted,
osteoclast formation or mononuclear TRAP cells were never
seen, as described previously 22. Unlike primary bone marrow
cells or BMM, RAW264.7 cells form osteoclasts without
M-CSF treatment; i.e. they require only RANKL stimulation.
Treatment of RAW264.7 cells with 17-AAG induced a dose-
dependent increase inHsp70 (Hspa1a) protein expression, con-
sistent with induction of theHSR (Fig. 1A), and, consistent with
previous findings (20, 21), 17-AAG also increased RANKL-
stimulated osteoclast formation in a dose-dependent manner
(Fig. 1, B and C). To confirm that this response was not unique
to RAW264.7 cells, examination of the effects of 17-AAG in
RANKL- and M-CSF-stimulated primary bone marrow cells
derived from C57Black/6 mice was performed. As with that of
the RAW264.7 cell line, 17-AAG significantly increased Hsp70
expression (Fig. 1D), and this was associated with a marked
increase in osteoclast formation (Fig. 1, E and F). It was noted
that the primary bone marrow cultures were more sensitive to
17-AAG with respect to the induction of the HSR and that this
correlated with increased osteoclast formation.
In RAW264.7 cells, 17-DMAG, a HSP90 inhibitor that is
structurally related to 17-AAG but more potently inhibits
HSP90, also enhanced both Hsp70 protein levels (Fig. 2A) and
RANKL-induced osteoclast formation (Fig. 2B) in a dose-de-
pendent manner, although at notably lower concentrations to
that of 17-AAG (Fig. 1, A and B).
To determine the scope of the effect, we examined whether
the structurally unrelatedHSP90 inhibitor radicicol had similar
effects to that of 17-AAG and 17-DMAG. Despite the differing
structure of radicicol, it was also found to significantly increase
Hsp70 levels (Fig. 2C) and significantly increase osteoclast for-
mation (Fig. 1D). However, in contrast to these findings, the
HSP90 inhibitors coumermycin A1 (Fig. 2E) and novobiocin
(Fig. 2G) did not significantly increase Hsp70 levels, thus failing
to induce a robust HSR. Moreover, coumermycin A1 (Fig. 2F)
and novobiocin (Fig. 2H) did not significantly increase oste-
oclast formation. These two HSP90 inhibitors bind the C-ter-
minal region of HSP90 and, thus, have a different mode of
action to that of 17-AAG, 17-DMAG, and radicicol. These
results are consistent with the notion that activation of Hsf1
and its ability to induce the HSR induced by N-terminal HSP90
inhibitors enhances RANKL-elicited osteoclast formation.
Pharmacological Inhibition of Hsf1 Reduces 17-AAG Enhance-
ment of RANKL-induced Osteoclast Differentiation—To further
investigate whether the HSR was mechanistically important
for 17-AAG-enhanced osteoclast formation, we examined
whether pharmacological inhibition of theHSRwould abrogate
the 17-AAG-mediated effect. Quercetin and KNK437 are two
compounds that have been shown to inhibit the HSR via
impacting Hsf1 functionality (36, 37). Consistent with this,
treatment of RAW264.7 cells with KNK437 (Fig. 3A) dose-de-
pendently inhibited the induction of Hsp70 protein expression
by 17-AAG and significantly abrogated the effects of 17-AAG
on RANKL-stimulated osteoclast formation (Fig. 3B), indicat-
ing a potential influence of Hsf1 on osteoclast formation. Quer-
cetin was also found to inhibit Hsp70 induction by 17-AAG
(Fig. 3C) and also significantly reduced the effects of 17-AAG
upon osteoclast formation (Fig. 3D). Of the two compounds,
KNK437 was more potent at inhibiting Hsp70 induction and,
consistent with this, was more effective at blocking 17-AAG
effects upon osteoclast formation (Fig. 3B). Interestingly, the
enhancement of osteoclast differentiation by TGF, a cytokine
known to stimulate NFATc1 expression (unlike 17-AAG (22))
and augment RANKL signals (38, 39), was not affected by
KNK437-mediated inhibition of Hsf1 (Fig. 3E). Thus, this dem-
onstrated a specificity of action of KNK437 upon stress-medi-
ated osteoclast formation and, more importantly, that of Hsf1
in 17-AAG-enhanced osteoclast differentiation.
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Hsf1 Knockdown Impairs the Effect of 17-AAG on
Osteoclastogenesis—To demonstrate a specific involvement of
Hsf1 upon 17-AAGactions in osteoclast formation, we reduced
Hsf1 expression by RNA interference methods. We utilized an
shRNAmir approach on the basis of the design of the primary
microRNA-30 transcript allowing for processing via the endog-
enous RNAi pathways and allowing for more specific silencing
than conventional shRNAi. RAW264.7 cells were transduced
using lentiviral constructs that expressed either a non-silencing
shRNAmir that had no homology to any known mammalian
genes or shRNAmirs with specificity for mouseHsf1. Immuno-
blot analysis of Hsf1 levels confirmed the efficient knockdown
of Hsf1 in RAW264.7 cells using two independent shRNAmirs
(Fig. 4A). Consistentwith the knockdownofHsf1, the 17-AAG-
mediated induction of Hsp70 was abrogated significantly (Fig.
4A). In non-silencing shRNAmir control RAW264.7 cells,
17-AAG strongly enhanced osteoclast formation, whereas
knockdown of Hsf1 by mir4 or mir5 significantly reduced the
effects of 17-AAG upon osteoclast formation (Fig. 4B), consis-
tent with the effects of the pharmacological inhibition of Hsf1.
Of interest, 17-AAG did not increase the steady-state levels of
Hsf1, but, consistent with it being a HSP90 client protein, Hsf1
levels were reduced. To ensure that abrogation of 17-AAG-
mediated effects upon osteoclast formation because of Hsf1
knockdown was not merely a result of an increased cell death,
we tested the sensitivity of the RAW264.7 cells to 17-AAG-
mediated cell death. In standard cell survival assays examining
increasing 17-AAG concentrations, no differences were
observed between the non-silencing control and Hsf1 knock-
down cells (Fig. 4C), indicating that any effects on osteoclast
formation were not due to alterations in cell survival.
Overexpression of Hsf1 Enhances 17-AAG Effects on RANKL-
induced Osteoclast Differentiation—To further investigate the
influence of Hsf1 in 17-AAG-enhanced osteoclast differentia-
tion, we examined the effect of overexpressingmousewild-type
Hsf1 in the RAW264.7 cell line. To achieve this, we transduced
RAW264.7 cells with retroviral vectors expressing mCherry
(control) or wild-type Hsf1 (Hsf1WT). Immunoblot analysis
FIGURE 1. 17-AAG enhances RANKL-dependent osteoclastogenesis and induces an HSR. A, murine osteoclast progenitor RAW264.7 cells showed an
increase in Hsp70 levels (immunoblot analysis) after treatment with indicated concentrations of 17-AAG for 24 h. B, RAW264.7 cells were cultured in 20 ng/ml
RANKL and the indicated concentrations of 17-AAG for 6 days, and osteoclasts (TRAP-positive MNCs) were counted. 17-AAG treatment dose-dependently
enhanced RANKL-dependent osteoclast formation. C, photomicrographs of osteoclasts formed in RANKL-treated RAW264.7 cell cultures showing increased
osteoclast formation in 17-AAG-treated (0.4M) cells comparedwith vehicle control (Veh. Ctl.).Red, TRAP staining. Scale bars100m.D, immunoblot analysis
of BMMs demonstrated elevated Hsp70 protein levels after treatment with 17-AAG (0.1 M) after a 24-h treatment period. E, as with RAW264.7 cells, mouse
bonemarrowcells cultured in 20ng/ml RANKL andM-CSF for 6days demonstrated a significant increase in TRAP-positiveMNCswith 0.1M17-AAG treatment.
F, photomicrographs of osteoclasts formed in mouse bone marrow cells cultured in 20 ng/ml RANKL and M-CSF for 6 days. Cultures with 17-AAG (0.1 M)
showed an increase in TRAP-positiveMNCswhen comparedwith vehicle control. Red, TRAP staining. Scale bars 100m. Error bars represent themean S.E.
of three independent experiments. *,p0.05; **,p0.01; ***,p0.001 relative toRANKL (20ng/ml)-treated vehicle control usingANOVA/Dunnett’s post hoc
test.
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demonstrated that, although there was a strong overexpression
of Hsf1 in the pBABE-Hsf1WT-transduced RAW264.7 cells,
Hsf1 was maintained in an inactive state, as demonstrated by
the comparative steady-state levels of Hsp70 and Hsp105
between control cells and Hsf1-overexpressing cells (Fig. 5A).
However, upon treatment with increasing concentrations of
17-AAG, Hsf1-overexpressing cells demonstrated an aug-
mented response, denoted by increased Hsp70 and Hsp105
expression (Fig. 5A) in comparison with the vector control
(pBABE-mCherry)-transduced cells. Consistent with this find-
ing, RAW264.7 cells overexpressing Hsf1 were more sensitive
to the effects of 17-AAG in enhancing osteoclast differentiation
(Fig. 5B). Notably, however, Hsf1 overexpression did not alter
the osteoclastogenic potential of RAW264.7 cells in the absence
of 17-AAG. Therefore, elevated Hsf1 levels appeared to sensi-
tize cells to the actions of 17-AAG rather than directly enhance
osteoclast differentiation.
17-AAG-enhanced Osteoclast Formation Is Impaired in Pri-
mary Bone Marrow Cells Derived from Hsf1/ Mice—To
extend our findings, we examined the role of Hsf1 in 17-AAG-
enhanced osteoclast formation in primary cells using bone
marrow cells derived frommice that were wild-type (Hsf1/),
heterozygous (Hsf1/), and null (Hsf1/) forHsf1. Immuno-
blot analysis showed that the expression level of Hsf1 in BMM
derived fromHsf/micewas undetectable, whereas its level of
expression in Hsf1/ BMM was observed to be significantly
lower than those isolated from wild-type (Hsf1/) mice (Fig.
6A). Consistent with the steady-state levels of Hsf1 in isolated
BMM, the induction of Hsp70 by 17-AAG was absent in the
Hsf1/ BMM and reduced significantly in the Hsf1/ BMM
when compared with Hsf1/ BMM (Fig. 6A). We then exam-
ined osteoclast formation in Hsf1/, Hsf1/, and Hsf1/
bone marrow cells (stimulated with 20 ng/ml RANKL and
M-CSF) in the presence of 17-AAG. We found that, in Hsf/
cell cultures, 17-AAG failed to significantly elevate osteoclast
numbers relative to vehicle control cultures, whereas in
Hsf1/ bone marrow cultures, 17-AAG significantly enhanced
osteoclast differentiation (Fig. 6, B and C). Bone marrow cell cul-
tures from Hsf1/ mice also showed a marked impairment of
17-AAG-enhanced osteoclast formation, consistent with the
decreased steady-state and activated levels of Hsf1 in these cells
(Figs. 6, B andC).
17-AAGTreatment EnhancesMITF Levels in anHsf1-depen-
dent Manner—MITF has been shown to be a critical regulator
of osteoclast formation and function (40–42), although the
regulation ofMITF protein expression in osteoclasts is not well
characterized. We have shown previously that, although
17-AAG has no enhancing effect upon major RANKL-elicited
intracellular signaling components (e.g. NFB, c-fos, and
NFATc1), we determined that 17-AAG did potently enhance
the cellular protein levels of MITF (22). Therefore, we investi-
gated whether 17-AAG enhanced MITF protein levels in a
manner that was mediated via Hsf1. We found that increased
MITF protein levels caused by 17-AAG treatment of
RAW264.7 cells was reduced significantly by pharmacological
inhibition of Hsf1 by KNK437 treatment (Fig. 7A). Similarly,
knockdown of Hsf1 by shRNAmir also inhibited the effect of
17-AAG upon MITF protein induction (Fig. 7B). Examination
of primary BMM cultures isolated from Hsf1/mice demon-
strated that MITF protein was low or undetectable by immu-
noblot analysis, either with or without 17-AAG treatment (Fig.
7C). Conversely, overexpression of Hsf1 in RAW264.7 cells
resulted in the elevation of MITF levels when compared with
control cells and was increased further with 17-AAG treatment
(Fig. 7D). These results indicate that 17-AAG increased
RANKL-induced osteoclast differentiation with increased
MITF protein levels, which wasmediated by the action of Hsf1.
FIGURE 2. Induction of an HSR by HSP90 inhibitors associates with
increased osteoclast formation. A, Hsp70 protein levels in RAW264.7 were
dose-dependently increased by 17-DMAG treatment after a 24-h period. B,
17-DMAG significantly increased osteoclast formation in RANKL-treated
RAW264.7 cells. C, the structurally unrelated HSP90 inhibitor radicicol
increased Hsp70 levels in RAW264.7 cells after a 24-h treatment period. D,
radicicol significantly increased osteoclast formation in RAW264.7 cells when
compared with vehicle control. The coumermycin A1 (E and F) and novobio-
cin (GandH) HSP90 inhibitors didnot induceaheat shock response, indicated
by a failure to increase Hsp70 levels in RAW264.7 cells and also failed to
increase osteoclast formation. Error bars represent the mean  S.E. of three
independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001 relative to
RANKL (20 ng/ml)-treated vehicle control using ANOVA/Dunnett’s post hoc
test.
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Ethanol and Chemotherapeutic Agents Enhance Osteoclast
Differentiation PotentiallyMediated by Hsf1—Hsf1 is activated
to counteract cellular damage and death caused by proteotox-
icity of a wide variety of chemical agents. In addition to HSP90
inhibitors, many cytotoxic chemotherapeutic agents also
potently activate Hsf1 and the HSR (43–46). Interestingly,
some cytotoxic chemotherapeutic agents are also known to
promote osteoclast formation (13). We hypothesized that at
least some stress-inducing agents, including some currently
used cytotoxic chemotherapeutics, may directly enhance oste-
oclastogenesis via activation of Hsf1 and the HSR (in a manner
similar to that of 17-AAG) if the agent was not too directly
toxic to RAW264.7 cells. We examined both ethanol, an oxi-
dative stressor that has been shown previously to enhance
osteoclastogenesis and induce the HSR (47, 48), and two
cytotoxic chemotherapeutic agents, doxorubicin and meth-
otrexate. Immunoblot analysis demonstrated that ethanol (Fig.
8A), doxorubicin (Fig. 8B), and methotrexate (Fig. 8C) all
increased Hsp70 protein expression in a dose-dependent man-
ner, consistent with their activation of Hsf1 and the HSR. Con-
sistent with our previous findings regarding HSP90 inhibitors
and the HSR, we observed that these three stressors, ethanol,
doxorubicin, and methotrexate, all enhanced RANKL-depen-
dent osteoclast formation in a dose-dependent manner in
RAW264.7 cells (Figs. 7,D–F). As with 17-AAG, pharmacolog-
ical inhibition of the HSR and Hsf1 by KNK437 in RAW264.7
cultures treated with ethanol (Fig. 7G), doxorubicin (Fig. 7H),
or methotrexate (Fig. 7I) inhibited the pro-osteoclastic effects
of the agents, although KN437 did not completely ablate the
effects of methotrexate. In sum, these results demonstrate that,
in addition to 17-AAG, other compounds that can induce Hsf1
activation and the HSR are also able to enhance RANKL-in-
duced osteoclastogenesis, potentially through a mechanism
that is at least partly Hsf1-dependent.
DISCUSSION
The ability of 17-AAG to cause bone loss and to increase
breast and prostate tumor growth and invasion in bone in
murine models indicates that this compound has potentially
serious negative effects on bone mass (20, 21). Although
17-AAG itself is not likely to be used clinically, functionally
similar, second-generation HSP90 inhibitors are currently
undergoing clinical trials andmay enter the clinic in the future.
Thus, it is imperative to elucidate their effects on bone. 17-AAG
and other HSP90 inhibitors have profound stimulatory effects
on osteoclast formation (20–22, 49), although contributing
influences of other cells to the observed bone loss cannot be
ruled out (50). In addition, increases in osteoclast numbers and
consequent increased bone resorption potentially increase the
risk of metastatic tumor growth in bone because of the release
of tumor growth factors from the bone matrix (51).
In this study, we demonstrated that 17-AAG and other stres-
sors act in an Hsf1-dependent manner to increase osteoclast
formation from their progenitors and that this may involve an
increase in the levels of the transcription factor MITF. We
investigated Hsf1 involvement in 17-AAG using a number of
approaches, including the use of pharmacological inhibition of
Hsf1 andHSRbyKNK437. This compound is a potent inhibitor
FIGURE 3. Inhibitors of Hsf1 decrease the effects of 17-AAG, but not TGF, on osteoclastogenesis in RANKL-treated RAW264.7 cells. A, immunoblot
analysis demonstrated that 24-h cotreatment of RAW264.7 cells with KNK437 ablated 17-AAG-induced Hsp70 protein induction. B, KNK437 inhibited 17-AAG-
enhancedosteoclast formation inRAW264.7 cells cultured for 6days in thepresenceof 20ng/ml RANKL.Veh. Ctl., vehicle control. Quercetin reduced theeffects
of 17-AAG treatment onHsp70protein expression after 24 hof treatment (C) and inhibited the effects of 17-AAGupon enhancedosteoclast numbers in RANKL
(20 ng/ml) treated RAW264.7 cells (D). E, RAW264.7 cells cultured with RANKL showed an increase in osteoclast numbers with TGF treatment. However, no
effects of KNK437 treatment were observed. Error bars represent the mean S.E. of four independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001
relative to RANKL-treated (20 ng/ml) vehicle control using ANOVA/Dunnett’s post hoc test.
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of Hsf1-induced expression of HSPs, such as HSP70, but does
not affect the basal levels of their constitutively expressed iso-
forms (36). It was notable that KNK437 administration at 10M
completely ablated 17-AAG actions on osteoclast formation
but did not decrease it below the control baseline levels induced
by 20 ng/ml RANKL alone. This concentration of KNK437 also
blocked Hsp70 induction. Quercetin, a widely distributed, nat-
urally occurring flavonoid, also reduces HSP induction and has
acceptable toxicity in clinical trials (52, 53). However, it should
be noted that quercetin also inhibits c-fos and NFB actions
that play a role in osteoclastogenesis, so its effects cannot be
assumed to be via Hsf1 alone (54, 55). Quercetin is not used in
any currently approved therapies but has been investigated for
anticancer and anti-inflammatory actions, so its clinical use to
ameliorate pathological bone loss is possible but has not yet
been investigated properly.
Tomore specifically address the role ofHsf1 in 17-AAGoste-
oclast effects, we targeted Hsf1 expression by shRNAmirs in
RAW264.7 cells. Knockdown ofHsf1 had a similar effect to that
of KNK437 in decreasing the effect of 17-AAG on RANKL-
induced osteoclast formation as well as inhibiting the induction
of HSP70 by 17-AAG. Bone marrow cells from Hsf1/ mice
were similarly defective in 17-AAG induction of osteoclast for-
mation. However, the ability of the progenitors to form oste-
oclasts was not impaired because osteoclast formation in
response to RANKL inHsf1/,Hsf1/, andHsf1/were all
comparable. Unfortunately, because of fertility problems in
these mice (56), we have not been able to undertake a system-
atic study of the bones or the influence of stressors on their
bone parameters. However, with a role for Hsf1 being estab-
lished, we also sought to identify the sufficiency of Hsf1 induc-
tion inmediating 17-AAG actions on osteoclasts. Ectopic over-
expression of Hsf1 (28) did not increase osteoclast formation
itself but did significantly increase the osteoclastic responsive-
ness of RAW264.7 cells to 17-AAG. The overexpressed Hsf1
probably remained in an inactive state because we observed no
alteration in the steady-state levels of HSP70, indicating that
FIGURE 4. Hsf1 knockdown greatly reduces the effect of 17-AAG upon
RANKL-induced osteoclastogenesis. A, lentivirus-transduced RAW264.7
cells with non-silencing (NS mir) or Hsf1-targeting shRNAmir (mir4 and mir5)
constructswere treatedwith the indicated concentrations of 17-AAG for 24h.
Immunoblot analysis demonstrated decreased Hsf1 protein levels, confirm-
ing knockdown. 17-AAG induction of Hsp70 protein was also impaired in the
Hsf1 knockdown RAW264.7 cells. B, Hsf1 knockdown resulted in a significant
reduction of the effects of 17-AAG on osteoclast formation in RAW264.7 cells
cultured in 20 ng/ml RANKL. C, a dose-response survival assay over 96 h in
RAW264.7 cells with indicated concentrations of 17-AAG demonstrated that
Hsf1 knockdown had no significant effect upon RAW264.7 cell survival. Error
bars represent themean S.E. of three independent experiments. *,p0.05;
**, p 0.01; ***, p 0.001 relative to RANKL-treated (20 ng/ml) vehicle con-
trol using ANOVA/Dunnett’s post hoc test.
FIGURE 5. Overexpression of Hsf1 enhances 17-AAG effects on RANKL-
induced osteoclastogenesis. A, RAW264.7 cells that had been retrovirus-
transduced with pBABE-mCherry control or pBABE-Hsf1WT-mCherry con-
structs were treated with the indicated concentrations of 17-AAG for 24 h.
Immunoblot analysis demonstrated that ectopic expressionofHsf1 increased
the levels of Hsp70 andHsp105 induced by 17-AAG in RAW264.7 cells. B, Hsf1
overexpression resulted in a significant increase in TRAP-positive osteoclasts
in RAW264.7 cells (cultured in 20 ng/ml RANKL) at increasing concentrations
of 17-AAG for 6 days relative to vehicle control. Data are presented as the
proportion relative to control (Rel. %) S.E. from three independent experi-
ments. *, p 0.05 relative to RANKL-treated (20 ng/ml) vehicle control using
ANOVA/Dunnett’s post hoc test.
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Hsf1 expression in itself is insufficient to increase RANKL-in-
duced osteoclast formation but requires activation.
In addition to 17-AAG, we have found other benzoquinone
ansamycins, such as herbimycin (20) and 17-DMAG, to also
significantly increase RANKL-induced osteoclast formation.
However, this actionwas not limited to this class of compounds
because other structurally distinct HSP90 inhibitors, such as
radicicol, NVP-AUY922, and CCT018159, also increased oste-
oclast formation (20, 22). Because these compounds all interact
with the N-terminal ATPase site of HSP90, causing inhibition,
it could be argued that ATPase site bindingmay be required for
their common actions, and although they greatly stimulate the
HSR, it may actually be the inhibition of HSP90 that is mecha-
nistically important for enhanced osteoclast formation (28, 57).
However, the HSP90 inhibitor novobiocin and its derivative
coumermycin A1, known to inhibit HSP90 by binding the
C-terminal of HSP90 and inhibiting its autophosphorylation
(thus altering both its chaperone activity and client protein
interactions), did not enhance RANKL-induced osteoclast for-
mation (58–60). Moreover, we have found no clear correlation
between the potency of theHSP90 inhibitors and their ability to
induce osteoclast formation. It should also be noted that these
compounds had aminimal effect on the induction of HSR, con-
sistent with previous observations that novobiocin causes a
dose-dependent decrease in Hsf1 DNA-binding and transcrip-
tional activities (61). Combined, these results suggest that
HSP90 inhibition per semay not enhance osteoclast formation
and is consistent with a role for the involvement of Hsf1 down-
stream target involvement.
Although Hsf1 itself has not been suggested previously to
play a role in osteoclast formation, several types of Hsf1-depen-
dent cellular stressors have been implicated in pathological
bone loss. These include chemotherapeutic agents, such as
doxorubicin andmethotrexate, that have been shown to cause a
decrease in trabecular bone volume in a rat model (13, 62).
Similarly, ethanol has been associated with the induction of
cellular stress and enhances bone loss in vivo through the
increase of osteoclast numbers (5). These observations provide
circumstantial evidence that Hsf1-dependent cell stress
induced by stimuli other than HSP90 inhibitors might indeed
enhance osteoclastogenesis, although there is no reason to
expect their actions to depend on a single mechanism. How-
ever, we confirmed here that ethanol, doxorubicin, and meth-
otrexate cause both enhanced osteoclast formation and a cellu-
lar stress response that could be ablated by Hsf1 inhibition by
KNK437. Thus, our results demonstrate, for the first time, that
compounds capable of activating Hsf1-dependent stress path-
ways can enhance osteoclastogenesis in a manner similar to
that of HSP90 inhibitors. It is important to note, however, that
compounds that are simply very toxic to cells or that inhibit
signaling essential to RANKL responses may not necessarily
drive increased osteoclast formation.
Our findings thatMITF levels may be involved in the actions
of 17-AAG are particularly interesting. MITF is a transcription
factor that is critical for osteoclast formation, as evidenced by
themi/mi strain of mice that lackMITF and are devoid of oste-
oclasts (63). In osteoclast progenitors, MITF levels are also
enhanced by RANKL, which triggers a signaling cascade by its
interaction with RANK, involving rapid induction of NFB,
p38, AP-1 andNFATc1 activity, and leading to increasedMITF
levels, typically after 24–48 h. The mechanism linking the ele-
vation of MITF levels to the induction by RANKL treatment
is currently controversial, but MITF is essential for many
(but not all) gene expression that is required by mature oste-
oclasts, including TRAP (acp5), cathepsin K (ctsk), and H
ion pump components (40, 64). This requires cooperation
FIGURE 6. The pro-osteoclastic effects of 17-AAG are impaired in bone
marrow cells derived from Hsf1 null mice. A, BMM derived from Hsf1/,
Hsf1/, andHsf1/micewere treatedwith the indicated concentrations of
17-AAG for 24 h. Immunoblot analysis showed a complete and partial reduc-
tionofHsf1protein inHsf1/ andHsf1/ cells, respectively. Consistentwith
this, no induction of Hsp70was observed inHsf1/ cells, whereas inHsf1/
cells, there was a substantial reduction. Ctl, control. B, primary bone marrow
cells derived from Hsf1/, Hsf1/, and Hsf1/ mice were cultured in 20
ng/ml RANKL, M-CSF, and the indicated concentrations of 17-AAG for 6 days,
fixed, and stained histochemically, and then TRAP-positive MNCs were
counted.Hsf1/ cells showeda lackof response to17-AAG,whereasHsf1/
cells demonstrated a marked diminished response to 17-AAG treatment in
terms of increased osteoclast formation. C, photomicrographs of TRAP-posi-
tive (red) osteoclast formation inHsf1/,Hsf1/, andHsf1/bonemarrow
cultures. Veh. Ctl., vehicle control. Scale bars 200 m. Error bars represent
the mean S.E. of three independent experiments. *, p 0.05; **, p 0.01;
***, p  0.001 relative to RANKL-treated (20 ng/ml) Hsf1/ control using
ANOVA/Dunnett’s post hoc test.
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betweenMITF and the transcription factor PU.1 (the latter is
not RANKL-dependent but binds MITF directly) together
with AP-1, NFB, and NFATc1. MITF is a relatively late-
activated factor in osteoclast commitment, and it is possible
that its induction by 17-AAG results in an increased pool of
MITF that may be otherwise rate-limiting. Consistent with
the latter, overexpression of MITF or the MITF-E isoform
(the latter isoform is a particular target of RANKL) enhances
osteoclast formation and action (65, 66). It should be noted
that because MITF ablation abolishes osteoclast formation,
its inhibition is not informative in addressing MITF media-
tion of 17-AAG effects.
FIGURE7.The inductionofMITFby17-AAGosteoclastprogenitor cells isdependentuponHsf1.A–D, proteinexpressionwasassessedby immunoblotting
of the indicated cell lysates.A, Hsf1 inhibitionbyKNK437 ablated 17-AAG-inducedMITF andHsp70protein levels after 24h in RAW264.7 cells.B, RAW264.7 cells
stably transduced with a lentiviral construct expressing Hsf1 shRNAmir showed a decrease in 17-AAG-induced MITF protein expression after 24 h. NS;
nonsilencing. C, BMM derived from Hsf1/ and Hsf1/mice were treated with M-CSF and the indicated concentrations of 17-AAG for 24 h. Hsf1/ BMM
showed lower MITF protein expression both with andwithout 17-AAG.D, RAW264.7 stably transducedwith a retroviral construct expressing Hsf1WT showed
an increase in MITF protein expression after 24 h of 17-AAG treatment.
FIGURE 8. Chemotherapeutic agents and ethanol induce a heat shock response and enhance RANKL-dependent osteoclastogenesis. Hsp70 protein
levels were induced in RAW264.7 cells by EtOH (A), doxorubicin (B), and methotrexate (C) over 24 h, as demonstrated by immunoblot analyses. D, RAW264.7
cells treatedwithRANKL showeda significant increase inosteoclast numbers after 6days incubationwith the indicatedconcentrationsof ethanol. Thiswas also
observed when cultures were treated with doxorubicin (E) and methotrexate (F). G, KNK437 treatment inhibited the action of ethanol as well as that of
doxorubicin (Dox., H) and methotrexate (MTX, I) on osteoclast formation in RANKL-treated RAW264.7 cells. Error bars represent the mean  S.E. of three
independent experiments. *, p 0.05; **, p 0.01; ***, p 0.001 relative to untreated control using ANOVA/Dunnett’s post hoc test.
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On the basis of our findings that 17-AAG increases MITF
levels and osteoclast formation in a manner sensitive to Hsf1
inhibition, we propose that 17-AAG-induced Hsf1 enhances
MITF protein levels and, thereby, amplifies the osteoclasto-
genic actions of RANKL. This proposed mechanism is summa-
rized in Fig. 9 and incorporates our earlier finding that tran-
scription factors activated early in the RANKL-dependent
signaling cascade are not induced by 17-AAG, including NFB,
c-fos (the regulated subunit of AP-1), and NFATc1 (22). The
latter findings suggested to us the possibility that a late-acting
factor such as MITF would be a more obvious candidate for
mediating 17-AAG actions. There is some evidence that MITF
can be induced by heat shock elicited byHsf1 via a direct action
on the MITF promoter (67). However, for stress-stimulated
osteoclast formation, it still has to be determined whether Hsf1
acts directly via MITF promoter interaction, by an indirect
mechanism such as increased HSP expression that may
increase MITF protein stability, or by a combination of both
direct and indirect mechanisms. Nevertheless, our findings
raise the possibility that any type of cell stress might enhance
the levels of this transcription factor, contingent upon other
effects the stressor exerts on cells. For example, some recently
developed HSP90 inhibitors, such as SNX-2112 and PF-
04928473, do not increase osteoclast formation at therapeuti-
cally relevant concentrations (49, 68) because, probably, these
agents are more potent than 17-AAG at causing degradation of
a number of HSP90 clients, such as NFB, c-fos, NFATc1, and
PU.1, which are critical for osteoclast differentiation.
In summary, we have identified a new role for Hsf1 and cell
stress in the enhanced formation of osteoclasts that may be
highly significant in bone physiology and pathophysiology
beyond our focus here on the HSP90 inhibitor 17-AAG. This
may result from enhancement of MITF levels, potentially
through a direct action ofHsf1 on theMITF promoter. 17-AAG
actions on osteoclasts may not be solely due to stress or Hsf1
induction, but, nevertheless, inhibition of Hsf1 seems to be a
potentially useful approach to reducing osteoclast formation
and osteolysis that may be induced by stressor compounds. If
stress responses do directly increase the formation of oste-
oclasts by increasing the responsiveness of osteoclast progeni-
tors to RANKL, we would speculate that other pathological
osteolytic stimuli might act, at least in part, by increasing stress
via Hsf1 activation and, thus, MITF levels, rather than increas-
ing local net RANKL levels. This raises the possibility that
blocking cell stress might reduce excessive pathological osteol-
ysis without necessarily abolishing the bone resorption
required for normal bone repair and remodeling.
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